Heat Biologics (HTBX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Noble Financial Sees Multiple Readouts for Heat Biologics (HTBX) by YE16; Maintains 'Buy' Rating
August 17, 2016 11:25 AM EDTNoble Financial affirms Heat Biologics, Inc. (HTBX) with a Buy rating and $8 price target following recent Q2 results.
Analyst Kumaraguru Raja sees multiple readouts for Heat Bio by the end of the year. Key points include:
Potential candidate for acquisition or collaboration. ImPACT based clinical programs, HS-410 in non-muscle invasive bladder cancer (NMIBC), and... MoreRoth Capital Keeps Heat Biologics (HTBX) at 'Buy' at Q4 Inflection Points Near
August 16, 2016 10:01 AM EDTRoth Capital affirms Heat Biologics (Nasdaq: HTBX) at Buy with a price target of $2.75 following Q2 results issued on Monday.
Analyst Joseph Pantgninis noted that the company is moving quickly towards inflection points slated for Q416. The analyst commented:
Heat expects to report top-line data in 4Q16 for its Phase II trial evaluating HS-410 for the treatment of non-muscle invasive bladder cancer (NMIBC) and its Phase Ib trial evaluating HS-110 in... More
